biostudies-arrayexpressMetabolomicsUnknownTranscriptomicsGenomicsProteomicsNicole Leonie BertschiIllumina NovaSeq 6000RNA-seq of coding RNAHomo sapiensHomo sapienshttps://www.ebi.ac.uk/biostudies/studies/E-MTAB-17321Effect of topical Tapinarof (VTAMA) on human Genoskin skin explants. Human Genoskin skin explants were treated with VTAMA(1% tapinarof) or Vehicle (control) for 2 and 5 days.biostudies-arrayexpressSample Collection - Skin explants were transferred immediately into culture medium. Prior to experimental manipulation, explants were equilibrated for at least 1 h at 37 °C in a humidified atmosphere containing 5% CO₂. Explants were cultured in 12-well plates for up to 5 days in a proprietary, chemically defined, hydrocortisone- and serum-free medium supplemented with penicillin (100 µg/mL) and streptomycin (100 µg/mL). Cultures were maintained at 37 °C and 5% CO₂, and culture medium was replaced daily. Skin explants were treated topically once daily with either vehicle control (Laboratoire Gola, Galenicare SA) or VTAMA (tapinarof cream, 1%, Dermavant Sciences) throughout the culture period.Library Construction - Illumina TruSeq Stranded mRNA protocol (Directional, first strand)Sequencing - The mRNA was sequenced by the Next Generation Sequencing Platform of Bern using paired-end 100 bp sequencing.Nucleic Acid Extraction - Total RNA from Genoskin samples was isolated using the RNeasy Lipid Tissue Kit (Cat. 74804, Qiagen) according to the manufacturer’s instructions.OrganizationMINSEQE ScoreAssays and DataMAGE-TAB FilesNicole Leonie BertschifalseRNA-seq of human Genoskin explants treated with topical VTAMA (tapinarof) against untreated controlEffect of topical Tapinarof (VTAMA) on human Genoskin skin explants. Human Genoskin skin explants were treated with VTAMA(1% tapinarof) or Vehicle (control) for 2 and 5 days.2026-07-26T00:00:00Z2026-07-26T01:00:49.512Z2026-07-15T21:37:19.557ZE-MTAB-17321ERP201291EFO_0002944EFO_0004170EFO_0005518EFO_0003738EFO_0004184